Speaker(s): 

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES, Staff Member, Duquesne University School of Pharmacy - has nothing to disclose.

Monica T. Dougherty, PharmD, BCACP, Staff Member, University of Rochester Medical Center - has reported the following disclosure(s): Pfizer ["Consultant/Advisor"]

Moderator(s): 

Daniel Longyhore, PharmD, EdD, BCACP, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Explain the psychosocial impact and treatment burden of pediatric atopic dermatitis (AD) on the quality of life for patients and their caregivers
• Analyze safety and efficacy data, novel mechanisms of action, and routes of administration of current FDA approved treatments for AD.
• Describe strategies to address caregiver concerns and barriers to biologic therapy initiation and adherence in pediatric patients with AD

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, EdD, BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH and Lisabeth Karetsky, CPhT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None